exv10w31w1






Exhibit 10.31.1




DISCLOSURE SCHEDULE




     In connection with that certain Common Stock Purchase Agreement (the “Agreement”) dated as of
December 14, 2010, by and between Cardica, Inc., a Delaware corporation (the “Company”)
and Aspire Capital Fund LLC., an Illinois limited liability company (“Aspire Capital”),
the Company hereby delivers this Disclosure Schedule to the Company’s representations and
warranties given in Section 3 of the Agreement. The section numbers in this Disclosure Schedule
correspond to the section numbers in the Agreement; provided, however, that any information
disclosed herein under any section number shall be deemed to be disclosed and incorporated in any
other section of the Agreement where such disclosure would be appropriate and reasonably apparent
from the face of the disclosure. Disclosure of any information or document herein is not a
statement or admission that it is material or required to be disclosed herein. References to any
document do not purport to be complete and are qualified in their entirety by the document itself.



Schedule 3(a) — Subsidiaries




     None.



Schedule 3(c) — Capitalization




     (iii)



Options and Awards As of November 30, 2010



In 1997, the Company adopted the 1997 Equity Incentive Plan (the “1997 Plan”). The 1997 Plan
provides for the granting of options to purchase common stock and the issuance of shares of common
stock, subject to Company repurchase rights, to directors, employees and consultants. Certain
options are immediately exercisable, at the discretion of the Board of Directors. Shares issued
pursuant to the exercise of an unvested option are subject to the Company’s right of repurchase
which lapses over periods specified by the board of directors, generally four years from the date
of grant. In February 2006, the Company terminated all remaining unissued shares under the 1997
Plan. Although the 1997 Plan terminated, all outstanding options thereunder will continue to be
governed by their existing terms.



In October 2005, the Company’s Board of Directors adopted, and in December 2005 the stockholders
approved, the 2005 Equity Incentive Plan, as amended (the “2005 Plan”). A total of 3,400,000
shares of common stock have been reserved for issuance under the 2005 Plan.



Stock awards granted under the 2005 Plan may either be incentive stock options, nonstatutory stock
options, stock bonuses or rights to acquire restricted stock. Incentive stock options may be
granted to employees with exercise prices of no less than the fair value of the common stock on the
date of grant, as determined by the Board of Directors, and nonstatutory options may be granted to
employees, directors or consultants at exercise prices of no less than the fair value. If, at the
time the Company grants an option, the optionee directly or by attribution owns stock possessing
more than 10% of the total combined voting power of all classes of stock of the






1.









 







Company, the option price shall be at least 110% of the fair value and shall not be exercisable
more than five years after the date of grant. Options may be granted with vesting terms as
determined by the Board of Directors. Options expire no more than 10 years after the date of grant,
or earlier if employment is terminated.



Common stock options may include a provision whereby the holder, while an employee, director or
consultant, may elect at any time to exercise the option as to any part or all of the shares
subject to the option prior to the full vesting of the option. Any unvested shares so purchased are
subject to repurchase by the Company at its option and at a price equal to the original purchase
price of the stock. The Company does not consider the stock issued upon exercise of an unvested
stock option substantively exercised, and the cash paid for the exercise price is considered a
deposit or a prepayment of the exercise price that is recognized by the Company as a liability. As
the underlying shares vest, the deposit liability is reclassified as equity. As of November 30,
2010, no such shares are subject to the Company’s right of repurchase and excluded from
stockholders’ equity.




	 	 	 	 	 

	Options outstanding
	 	 	3,377,681	 
	Restricted awards outstanding
	 	 	38,675	 
	 
	 	 	 
	 
	 	 	3,416,356	 
	 
	 	 	 
	 
	 	 	 	 
	Option shares available for future grant
	 	 	863,389	 
	 
	 	 	 





Warrants to Purchase Common Stock As of November 30, 2010



As of November 30, 2010, warrants to purchase 4,646,393 shares of common stock were outstanding, of
which warrants to purchase 4,071,046 shares of common stock were exercisable at $1.45 per share and
warrants to purchase 575,347 shares of common stock were exercisable at $5.65 per share. The
warrants expire at various dates from June 2012 to September 2014. Additional information about
the warrants is available upon request.




     (iv) The Company has entered into the following agreements under which the Company is
obligated to register the sale of their securities under the 1933 Act:


Registration Rights Agreement, dated June 7, 2007, by and among Cardica, Inc., and the purchasers
listed on the signature pages thereto.



Registration Rights Agreement, dated September 25, 2009, by and among Cardica, Inc., and the
purchasers listed on the signature pages thereto.



Registration Rights Agreement, dated August 16, 2010, by and between Cardica, Inc., and Intuitive
Surgical Operations, Inc.




Schedule 3(e) — No Conflicts



On June 21, 2010, we received a letter, dated June 21, 2010, from the Listing Qualifications
Department of The NASDAQ Stock Market notifying us that we did not comply with the $50.0 million
minimum market capitalization for continued listing on The NASDAQ Global Market set




2.









 







forth in NASDAQ Marketplace Rule 5450(b)(2)(A) or the Minimum Market Capitalization Standard. On
September 16, 2010, we received a letter from the Listing Qualifications Department of The NASDAQ
Stock Market notifying us that we had regained compliance with the Minimum Market Capitalization
Standard.




Schedule 3(f) — 1934 Act Filings




     Not applicable.



Schedule 3(g) — Absence of Certain Changes




     Not applicable.



Schedule 3(h) — Litigation



On July 22, 2010, the Company was served with a complaint filed by Precision Made Products, LLC
(“PMP”) in state court in Ohio alleging claims for breach of contract by the Company for failing to
pay for certain services and/or products provided by PMP and claims for intentionally and/or
negligently making representations relating to the contract. The Company denies the allegations
in the Complaint. The Company has filed a counterclaim asserting claims for breach of contract for
PMP’s failure to perform and for damage to the Company arising from this breach.




Schedule 3(j) — Intellectual Property Rights




     Not applicable.



Schedule 3(l) — Title




     Not applicable.



Schedule 3(p) — Transactions with Affiliates




Sales of Stock and Warrants to Officers and Directors



In June 2007 and in September 2009, the Company entered into securities purchase agreements in
connection with private placements to accredited investors, some of which included certain
individuals and entities affiliated with the Company and officers of the Company. Pursuant to the
terms of the June 2007 and September 2009 securities purchase agreements, certain individuals and
entities affiliated with the Company and officers of the Company purchased shares of common stock
and warrants to purchase shares of common stock of the Company. In connection with the private
placements, the company also entered in registration rights agreements in June 2007 and September
2009 with the purchasers of common stock and warrants, which include certain individuals and
entities affiliated with the Company or its directors and officers of the Company.








3.









 








Life Insurance



The Company pays the premiums on a life insurance policy on Dr. Bernard A. Hausen’s behalf.




 [Remainder of Page Intentionally Left Blank]





4.